Clinical Trials Logo

Neoplasm Metastasis clinical trials

View clinical trials related to Neoplasm Metastasis.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06106568 Active, not recruiting - Liver Metastases Clinical Trials

An Observational Study to Learn More About the Impact of Gadoxetate Sodium-Enhanced Magnetic Resonance Imaging (EOB-MRI) When Used to Diagnose the Spread of Cancer From the Pancreas to the Liver in Japanese People Under Real-World Conditions

Start date: November 20, 2023
Phase:
Study type: Observational

This is an observational study in which data from people with cancer that has spread from the pancreas to the liver are collected and studied. These adults will include people who already received their usual treatment and who have had a certain type of imaging scan before the diagnosis of pancreatic cancer. Metastatic pancreatic cancer is a cancer that starts in the pancreas, a gland that helps to digest food, and has spread to other parts of the body. Pancreatic cancer most commonly spreads to the liver (called liver metastasis). Gadoxetate sodium-enhanced magnetic resonance imaging (EOB-MRI) is a type of imaging technique that uses a specific dye called gadoxetate sodium to produce clearer images of the liver. Participants with pancreatic cancer can be treated with surgery only if their cancer has not spread to other parts of the body. Therefore, it is important to find out if the cancer has spread to other parts of the body before performing surgery. To do this, different imaging scans such as exploratory laparoscopy and CE-CT are used. However, these tests have certain limitations, such as complicated procedures or, in some cases inaccurate results. Some studies suggest that performing EOB-MRI along with a regular CT scan may improve the chances of finding out if pancreatic cancer has spread to the liver. This imaging technique is especially helpful in detecting smaller tumors that may be missed in other types of scan. However, more information is needed to better understand the impact of EOB-MRI in Japanese people under real-world conditions. The main purpose of this study is to learn more about how using EOB-MRI helps in deciding the treatment options, how well the participants do, and how much does the use of medical care facilities costs. The main information that researchers will collect in this study: participant characteristics, including age, sex, whether they smoke or not, how well they can manage daily tasks, any other health problems they have, how advanced their cancer is, and if they have undergone laparoscopy the length of time: from the date of diagnosis of pancreatic cancer until a participant dies (called overall survival) from the date of first treatment for pancreatic cancer until the cancer spreads of other organs from the date of diagnosis of pancreatic cancer to starting the first treatment from the date of first treatment for pancreatic cancer to starting the second treatment option treatments that the participants have received, including anti-cancer drugs, radiation, and surgery the number of hospital visits, use of healthcare facilities, and related costs. The information in this study will be grouped based on the participants who had an EOB-MRI and those who had non EOB-MRI. The data will come from the participants' information stored in a database called Medical Data Vision (MDV) in Japan. Data collected will be from January 2011 to October 2022. Researchers will track individual patients' data for at least 1 year, until death, until there is no health record in the MDV for 2 months after treatment starts, or until the end of study. In this study, only available data from health records are collected. No visits or tests are required as part of this study.

NCT ID: NCT06083662 Active, not recruiting - Metastatic Cancer Clinical Trials

Neratinib and Trastuzumab Biosimilar in Patients With HER2 Mutated Advanced Solid Cancers

Start date: June 15, 2021
Phase: Phase 2
Study type: Interventional

Prospective, Basket, Open-label, Multi-dose, Single-arm, Simon's two-stage, Multi-center trial Study drug : neratinib + herzuma (trastuzumab biosimilar)

NCT ID: NCT05997082 Active, not recruiting - Clinical trials for Burnout, Professional

A Mindful Self-compassion Based Intervention for Specialist Rehabilitation Providers

Start date: July 13, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore the impact of an online compassion-based intervention on burnout among specialist rehabilitation providers. Post-intervention interviews aim to gather information on: burnout and compassion, experiences with the intervention, barriers and facilitators to taking part, and suggestions for improving online course delivery.

NCT ID: NCT05827965 Active, not recruiting - Clinical trials for Fasting, Intermittent

Ramadan Fasting in Secondary Adrenal Insufficiency Patients

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Intermittent Ramadan fasting was associated with a risk of complications in patients with adrenal insufficiency. A risk stratification with recommendations (lifestyle and drug adjustment) for fasting in these patients has been recently published. So, this prospective interventional study was carried out to evaluated these recommendations. Patients with secondary adrenal insufficiency and willing to fast Ramadan were included. Before Ramadan, patients underwent a clinical examination and were educated for lifestyle measures and the schedule of glucocorticoid replacement therapy was adjusted. The occurrence of complications and the number of fasted days during the month of Ramadan 2023 were reported and compared with those of Ramadan 2022.

NCT ID: NCT05704933 Active, not recruiting - Metastatic Melanoma Clinical Trials

Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases

Start date: June 6, 2023
Phase: Early Phase 1
Study type: Interventional

The purpose of this pilot study is to determine the safety and feasibility of giving a single dose of Nivolumab with Ipilimumab or Relatlimab in participants with brain metastases from melanoma who can undergo surgery for removal of their brain metastases 7- 10 days after receiving the study drug.

NCT ID: NCT05663411 Active, not recruiting - Clinical trials for Secondary Hyperparathyroidism

A Study of SHR6508 in Secondary Hyperparathyroidism

Start date: February 24, 2023
Phase: Phase 2
Study type: Interventional

The study is being conducted to evaluate the efficacy and safety of SHR6508 for Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.

NCT ID: NCT05555342 Active, not recruiting - Metastatic Cancer Clinical Trials

A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm

Start date: January 3, 2023
Phase: Early Phase 1
Study type: Interventional

This is a phase 0, pilot prospective study to determine the feasibility of combined irreversible electroporation (IRE) and radiation therapy in subjects with lung tumors with metastatic cancer of any histology. These are subjects who have advanced disease (stage IV) or previously treated disease that has become progressive, recurrent, or metastatic.

NCT ID: NCT05376579 Active, not recruiting - Clinical trials for Active Secondary Progressive Multiple Sclerosis

Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

ITASIA
Start date: June 17, 2022
Phase:
Study type: Observational

This is an observational, multicenter, single-arm, prospective study conducted in Italy

NCT ID: NCT05339945 Active, not recruiting - Metastatic Cancer Clinical Trials

Towards an Early Integration of Palliative Care in Oncology

BESACE
Start date: June 2, 2022
Phase:
Study type: Observational

The primary objective of the study is to describe the nature and to estimate the prevalence the health needs of patients with metastatic cancer and their main caregivers, between the period from diagnosis to death. As secondary objectives, the study aims: - to determinate the proportion of patients with an indication for palliative care according to Hui et al., and to describe the adequation of health needs and the services for them; - to study the association between clinical pathway and the indication of targeted palliative care; - to study the association between the integration of palliative care service and the adequation of health needs service of patients; - to study the factors such as the disease, the practice and the care, contribute to the patient's survivor of 1 year.

NCT ID: NCT05324046 Active, not recruiting - Liver Metastases Clinical Trials

Comparison Between LDCT With DL Recontruction and Standard Dose CT

Start date: June 2, 2022
Phase:
Study type: Observational

This prospective study aims to perform intra-individual comparison of the image quality between low dose liver CT with deep learning reconstruction and standard dose liver CT with iterative reconstruction in patients with liver metastasis.